The fresh trigger for Novo Nordisk (CPSE:NOVO B) is a CHMP green light for FREHEMGO, a haemophilia A therapy that could add a rare-disease revenue stream alongside its core obesity and diabetes portfolio. Novo Nordisk has packed several catalysts into September, yet the share price tells a different story, with a 30 day share price return of down 5.7% and a year to date share price return of down 15.4% despite today's 2.5% one day gain to DKK279.35. Over a longer stretch, the total shareholder return paints an even colder picture, down 25.4% over one year and more than 50% over three years.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.